OREXIGEN THERAPEUTICS, INC. (a Delaware corporation)Purchase Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
Orexigen Therapeutics, Inc., a Delaware corporation (the “Company”) confirms its agreement with Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch is acting as representative (in such capacity, the “Representative”), with respect to (i) the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in said Schedule A, and (ii) the grant by the Company to the Underwriters of the option described in Section 2(b) hereof to purchase all or any part of l additional shares of Common Stock to cover overallotments, if any. The aforesaid l shares of Common Stock (the “Init
LICENSE AGREEMENTLicense Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
THIS AGREEMENT made and entered into this 1st day of June, 2004 (“EFFECTIVE DATE”), by and between LEE G. DANTE, an individual having his principal office at [***] (“DANTE”), and OREXIGEN THERAPEUTICS, INC., a corporation organized under the laws of Delaware (“OREXIGEN”), with its corporate headquarters and principal office at One Palmer Square, Suite 515, Princeton, NJ 08540.
LICENSE AGREEMENTLicense Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
THIS AGREEMENT made and entered into this 3rd day of January, 2005 (“EFFECTIVE DATE”), by and between OREXIGEN THERAPEUTICS, INC., a Delaware corporation (“OREXIGEN”), and CYPRESS BIOSCIENCE, INC., a Delaware corporation (“CYPRESS”).
LICENSE AGREEMENT BETWEEN Oregon Health & Science University AND OrexigenLicense Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • Oregon
This License Agreement is made and entered into on this 27th day of June, 2003 (hereinafter “Effective Date”) by and between Oregon Health & Science University (hereinafter “OHSU”), having offices at 2525 SW 1st Ave, Portland, Oregon 97201, and Orexigen Therapeutics, Inc. (hereinafter “LICENSEE”), a Delaware corporation having offices at 28202 Cabot Road, Suite 200, Laguna Niguel, CA 92677.
LICENSE AGREEMENTLicense Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of January 20, 2004, by and among Orexigen Therapeutics, Inc., a Delaware corporation (the “Company”), the parties listed on Schedule A hereto (collectively, the “Investors” and each individually, an “Investor”).
MASTER AGREEMENT FOR PHARMACEUTICAL DEVELOPMENT SERVICESMaster Agreement for Pharmaceutical Development Services • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • Ohio
RESEARCH AGREEMENT #2Research Agreement • April 9th, 2007 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
This Research Agreement (this “Agreement”) is entered into between Orexigen Therapeutics, Inc. with offices at 12481 High Bluff Drive, San Diego, CA 92130, hereinafter referred to as “SPONSOR”, and the Oregon Health & Science University, a non-profit, public corporation of the state of Oregon, located at 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, hereinafter referred to as “UNIVERSITY”.
